UPS Invests US$48m into Global Supply Chain Strategy

UPS has committed US$48m to expand its temperature-controlled logistics infrastructure across 27 facilities in Europe, Asia and the Americas. The investment could position the company to capture a larger share of the growing biologics market as pharmaceutical supply chains face new complexity.

According to Growth Market Reports, demand for temperature-sensitive biologics could reach US$39.1bn by 2033. This creates a commercial opportunity for logistics providers which can meet strict handling requirements.

The pharmaceutical sector is experiencing a fundamental shift in product composition and handling demands. Traditional small-molecule drugs are increasingly being supplemented by complex biologics that require precise environmental controls throughout the supply chain. This transition is reshaping logistics infrastructure requirements and creating pressure on providers to upgrade capabilities.

Investment targets market expansion

The cross-dock facilities will optimise speed and short-term storage across air and ground movements. Products will be maintained within controlled temperature ranges of two to eight degrees Celsius, frozen capabilities or 15 to 25 degrees Celsius.

UPS operates more than 19.2m square feet of cGMP and GDP-compliant healthcare distribution space globally. The company provides services across more than 200 countries and territories.

The scale of this infrastructure network provides UPS with geographic coverage that supports both established and emerging pharmaceutical markets. This positioning becomes increasingly valuable as drug manufacturers seek to expand patient access across diverse regions with varying regulatory frameworks.

According to Kate Gutmann, EVP and President of International, Healthcare and Supply Chain Solutions at UPS, the company has aligned investments with customer needs.

She says: "We have aligned our investments with our Healthcare customers' specialised needs. Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world.

"This effort, and all of our work in healthcare logistics, extends from a deep understanding that we're doing more than moving packages. We are helping patients access the medications and treatments they need."

Growth driven by biologic complexity

Cell and gene treatments, mRNA platforms and GLP-1 injectables are entering the market with more demanding logistics requirements. Temperature control failures carry an estimated annual cost of up to US$35bn.

According to the World Health Organisation, temperature failures contribute to up to 50% of global vaccine waste. This represents both a financial risk and a service delivery challenge for logistics providers.

PharmaSource data shows approximately one in three newly approved drugs is a biologic created from living cells. More than 85% of these require temperature-controlled handling.

The expansion builds on UPS acquisitions including Bomi Group, Frigo Trans and BPL in Europe, plus Andlauer Healthcare Group in North America. The company has also expanded its Incheon, Korea air hub to improve pharmaceutical trade flows.

These strategic acquisitions have enabled UPS to integrate regional expertise and established customer relationships into its broader network. The approach combines local market knowledge with global infrastructure coordination, creating operational advantages in markets where regulatory compliance and customer service expectations vary significantly.

Integrated network reduces handling risks

A fragmented network with multiple handoffs increases the risk of product mishandling. UPS uses a single integrated network to provide customers with accountability and real-time oversight for each shipment.

The company operates a control tower that monitors shipments around the clock. The facility tracks risks and supports intervention to keep products moving.

John Bolla, President of UPS Healthcare, says the investments reflect a commitment to supply chain protection. John states: "Biologics and personalised treatments are driving better, more targeted care for patients."

He adds: "These investments reflect our commitment to strengthening our end-to-end supply chain that helps protect innovative treatments and diagnostics, supporting better patient outcomes."